CDx Diagnostics®
Robert received an undergraduate degree in Physics from Fordham University, a Bachelor's and Master's Degree in Electrical Engineering from Columbia University, in a relatively short time span of 6 years. In 1988, he worked as a Research Associate with Dr. Leopold Koss at Montefiore Hospital to develop classifiers to recognize cancer cells in voided urine using image processing and multivariable statistical analysis. In 1990, he joined Neuromedical Systems, a startup company, to develop a premier application to sort cancer cells in cervical pap smears using neural networks. He was instrumental in submitting a PMA to the FDA as a medical device. Its success lead to a successful IPO of 30 million dollars.
For a year, he worked for TriPath Imaging to develop a virtual microscope, a universal plug-in to work with a multitude of microscopes. Subsequently, he worked for Physiome Sciences to develop computerized physiological models of human and animal cells, to understand and accelerate the development of pharmaceutical drugs. Starting in 2003, at OralCDx, Robert developed the next generation high-resolution scanner system and developed specific technologies to further increase both the image quality and overall accuracy and sensitivity of the system to analyze thick brush biopsy samples.
This person is not in any offices
CDx Diagnostics®
The mission of CDx Diagnostics® is to provide clinicians with easily implemented, cost-effective tools to preempt cancer through enhanced detection of precancerous cellular changes. This is accomplished by a proprietary diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods.